StreetAlpha
13F holdings · Q3 2026

Armistice Capital

New York, NY · files as Armistice Capital, LLC
Know the moment Armistice Capital filesYou follow Armistice Capital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1601086

Armistice Capital reported 333 stocks worth $3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are SUPN (3.7%), AGIO (2.9%) and PTCT (2.8%). Compared with Q2 2026, the fund opened new positions in TLX, GEHC and BNTX, added to AGIO, PTCT and NBIX, trimmed SUPN, CYTK and TVTX and sold out of HUM, ILMN and PBH.

Latest filing: what Armistice Capital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
158 new69 added83 trimmed148 sold outBought about $261M · sold about $862M
New 158
See all 158 →
Added 69
See all 69 →
Trimmed 83
  • MDGL−$98.8M−68%
  • TMO−$61.1M−74%
  • INCY−$36.4M−33%
  • UNH−$34.1M−51%
  • REGN−$25.1M−37%
See all 83 →
Sold out 148
See all 148 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$3B−17.5% vs last quarter · $8.2B including options
Stocks held333158 new · 148 sold out
Top 5 weight14.7%spread out
Turnover46%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
SUPN
Supernus Pharmaceuticals Inc
$110M3.7%2.5M−98K (−4%)8 of 8
2
AGIO
Agios Pharmaceuticals Inc
$85.7M2.9%2.6M+178K (+7%)8 of 8
3
PTCT
Ptc Therapeutics Inc
$84.1M2.8%1.3M+226K (+21%)8 of 8
4
NBIX
Neurocrine Biosciences Inc
$80.2M2.7%565K+29K (+5%)8 of 8
5
CYTK
Cytokinetics Inc
$77.8M2.6%1.2M−21K (−2%)8 of 8
6
TVTX
Travere Therapeutics Inc
$75.9M2.5%1.3M−283K (−18%)8 of 8
7
RIGL
Rigel Pharmaceuticals Inc
$74M2.5%1.5M−136K (−8%)8 of 8
8
INCY
Incyte Corp
$72.8M2.4%600K−300K (−33%)8 of 8
9
IRWD
Ironwood Pharmaceuticals Inc
$59.5M2.0%15M+1.1M (+8%)8 of 8
10
IMVT
Immunovant Inc
$58.7M2.0%1.7M+2,169 (+0%)8 of 8
🔒 323 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
HUM
Humana Inc
$28.8M73K
ILMN
Illumina Inc
$16M91K
PBH
Prestige Consmr Healthcare I
$15.9M336K
FWONK
Liberty Media Corp Del
$15.7M165K
ITGR
Integer Hldgs Corp
$15.7M168K

🔒 Free account: see all 30.

Options

valued at the underlying shares
StockTypeValueSharesChange
SPY
Spdr S&P 500 ETF TR
Call$2.6B3.4M+3,350,000
IWM
Ishares TR
Call$1.8B6.6M+6,600,000
CYTK
Cytokinetics Inc
Call$169M2.6M+1,030,000
MDGL
Madrigal Pharmaceuticals Inc
Call$129M255K+255,000
AGIO
Agios Pharmaceuticals Inc
Call$110M3.3M+495,100

🔒 Free account: see all 13.

Reported value

last 8 quarters
$4.3BQ4 '24
$3.7BQ1 '25
$2.6BQ2 '25
$3.2BQ3 '25
$4.1BQ4 '25
$3BQ1 '26
$3.6BQ2 '26
$3BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Armistice Capital 13F FAQ

What does Armistice Capital own?

Armistice Capital reported 333 stocks worth $3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are SUPN (3.7%), AGIO (2.9%) and PTCT (2.8%). The table above lists every position in the filing (the top 10 without an account).

What did Armistice Capital buy and sell in Q3 2026?

Compared with Q2 2026: 158 new positions, 69 added to, 83 trimmed and 148 sold out. New positions include TLX, GEHC and BNTX. It sold all of HUM, ILMN and PBH.

When will Armistice Capital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Armistice Capital's portfolio worth?

The Q3 2026 filing reports $3B in US stocks ($8.2B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.